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Abstract Tamoxifen induces apoptosis (programmed cell
death) in human erythroleukemia K562 cells. Nitric oxide
synthase activity and expression increased in apoptotic cells by
315% and 280%, respectively, compared to controls. The specific
inhibitor of nitric oxide synthase, L-NAME, protected K562 cells
from tamoxifen-induced apoptosis, whereas the nitric oxide
donor, sodium nitroprusside (SNP), potentiated the apoptotic
effect of the drug. In addition, 5-lipoxygenase was activated by
tamoxifen and the specific enzyme inhibitor, MK886, protected
K562 cells against the drug. Conversely, the 5-lipoxygenase
product, 5-hydroperoxyeicosatetraenoic acid, enhanced the
tamoxifen-induced apoptosis. Finally, tamoxifen altered also
membrane properties of K562 cells.
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1. Introduction
Tamoxifen (Tmx) reduces the proliferation of several neo-
plasms [1] and is active against tumors such as melanoma [2],
hepatoma [3] and uterine leiomyoma [4]. In particular, Tmx is
commonly used as chemotherapeutic agent in human breast
cancer and is also currently being used in trials on estrogen-
negative breast cancer patients [5]. In a previous study, we
showed that Tmx induces signi¢cant apoptosis (programmed
cell death, PCD) in human breast MCF-7G cells [6]. Similar
results have also been reported for breast cancer cells [7,8],
macrophages [9] and brain tumor cells [10]. Tmx has also been
reported to exert its action on blood cells of breast cancer
patients: it forms DNA adducts [11], modulates the multidrug
resistance pump, P-glycoprotein [12], and a¡ects calcium me-
tabolism [10]. This evidence suggests that the drug has a com-
plex mechanism of action [13]. Nitric oxide [14,15] and mem-
brane-derived lipid messengers [14,16^21] have recently
become the focus of many research e¡orts, as they appear
to play an important role in the regulation of apoptosis. In
this study, human erythroleukemia K562 cells were found to
be highly sensitive to Tmx-induced PCD, and were used to
elucidate biochemical events of the apoptotic programme in-
duced by the drug.
2. Materials and methods
2.1. Materials
Chemicals were of the purest analytical grade. Arachidonic (eicosa-
tetraenoic) acid, 5-hydroperoxyeicosatetraenoic acid (5-HPETE), [Z]-
1-[p-dimethylaminoethoxyphenyl]-1,2-diphenyl-1-butene (tamoxifen),
ATP, Ng-nitro-L-arginine methyl ester (L-NAME), sodium nitroprus-
side (sodium nitroferricyanide, SNP), ribonuclease (RNase) and pro-
pidium iodide were purchased from Sigma. L-[2,3,4,5-3H]Arginine
(speci¢c activity = 64 Ci/mmol = 2.37 TBq/mmol) was from Amersham.
Leukotriene B4 (LTB4) was from Cayman. Trypsin, L-glutamine and
non-essential amino acids were purchased from Flow Laboratories.
The culture media Ham’s F-12 and Minimal Essential Medium
(MEM) were from Gibco; fetal calf serum was from Hy Clone; cho-
lesterol oxidase was provided by Boehringer Mannheim. Lympholyte-
H was from Cedarlane Laboratories. Annexin V-FITC (£uorescein
isothiocyanate) conjugate was purchased from Brand Applications.
5-Lipoxygenase speci¢c inhibitor 3-[1-(p-chlorobenzyl)-5-(isopropyl)-
3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid (MK886) and
anti-human 5-lipoxygenase rabbit polyclonal antibodies were a kind
gift from Dr. A.W. Ford-Hutchinson (Merck Frosst Centre for Ther-
apeutic Research, Canada). Anti-inducible nitric oxide synthase
monoclonal antibodies were purchased from Transduction Laborato-
ries. Goat anti-rabbit and goat anti-mouse antibodies, both conju-
gated with alkaline phosphatase (GAR-AP or GAM-AP, respec-
tively), were purchased from Bio-Rad.
2.2. Cell culture and treatment
Human erythroleukemia K562 cells were grown in a 1:1 mixture of
MEM and Ham’s F-12 media, supplemented with 12% heat-inacti-
vated fetal calf serum, 1.2 mg/ml sodium bicarbonate, 1% non-essen-
tial amino acids, 2 mM L-glutamine and 15 mM HEPES bu¡er, pH
7.4. Mycoplasma-free cell cultures were maintained at 37‡C in a hu-
midi¢ed atmosphere with 5% CO2. K562 cells were grown in suspen-
sion at a density of 0.5U106 cells/ml and were split 1:7, twice weekly.
Drug exposure of K562 cells (100U106/test) was performed by adding
1 WM tamoxifen to the culture medium [6]. The e¡ect of various
concentrations of L-NAME, SNP, MK886 or 5-HPETE on tamoxi-
fen-induced apoptosis was evaluated using 10U106 K562 cells/test.
Cells were grown for 48 h at 37‡C, in a humidi¢ed atmosphere with
5% CO2, and were then washed by centrifugation at 800Ug for 5 min
and counted in a Neubauer cytometer chamber. Cell viability was
assessed by Trypan blue dye-exclusion.
Dying K562 cells were separated from the whole cell population by
gradient centrifugation, using the density separation medium Lym-
pholyte-H, according to the manufacturer’s instructions (Cedarlane
Laboratories). A suspension of 100U106 K562 cells in 8 ml culture
medium was carefully layered over 4 ml Lympholyte-H in a 15-ml
centrifuge tube. Since Lympholyte-H is more dense than the cell sus-
pension, a distinct interface is formed. After centrifugation at 800Ug
for 20 min, at room temperature, a well-de¢ned layer of live cells
(lower density) was evident at the interface between the two £uids
at di¡erent densities, whereas dead cells (higher density) formed the
pellet. Using a Pasteur pipette, dead cells were transferred to a new
centrifuge tube and subjected to a new round of gradient centrifuga-
tion.
2.3. Evaluation of cell death
K562 cells (1U106) were collected by centrifugation at 800Ug for
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5 min and were ¢xed in a 1:1 solution of phosphate-bu¡ered saline
and methanol/acetone (4:1, by vol.). Cells were washed in phosphate-
bu¡ered saline and incubated with 13 kU RNase for 20 min, at 37‡C,
then with 40 Wg/ml propidium iodide for 15 min, at 37‡C. The number
of apoptotic bodies was evaluated by £ow cytometry using a propi-
dium iodide staining [22] on a FACScan £ow cytometer (Becton-Dick-
inson). Cells were excited at 488 nm using a 15-mW Argon laser, and
£uorescence emitted at 570 nm was measured. Five thousand events
were evaluated by the Lysis II Program (ibid.), using an electronic
gating FSC-H/FSC-A/SSC to eliminate cell aggregates.
2.4. Determination of enzyme activity and expression
The activity of nitric oxide synthase (EC 1.14.13.39) was assayed by
incubating cell extracts with the radiolabelled substrate [3H]arginine,
and then isolating and quantifying the reaction product [3H]citrulline
as described [23]. Nitric oxide synthase activity was expressed as pmol
citrulline formed per min per mg protein. The activity of 5-lipoxyge-
nase (EC 1.13.11.34) in K562 cells was assayed by incubating cell
extracts for 10 min at 37‡C in the presence of 1 mM ATP, 2 mM
CaCl2 and 40 WM arachidonic acid, as reported [24]. 5-Lipoxygenase
activity was expressed as nmol 5-hydroperoxyeicosatetraenoic acid
(5-HPETE) formed per min per mg protein. Protein concentration
of cell extracts was determined according to Bradford [25]. Enzyme-
linked immunosorbent assay (ELISA) of K562 cell extracts was per-
formed as reported [20], using 25 Wg proteins/well. Anti-inducible
nitric oxide synthase monoclonal antibodies (diluted 1:400) or anti-
5-lipoxygenase polyclonal antibodies (diluted 1:200) were used as ¢rst
antibody. Goat anti-mouse or anti-rabbit immunoglobulins conju-
gated with alkaline phosphatase (GAR-AP or GAM-AP, respectively)
were used as second antibody, diluted 1:2000. Color development of
the alkaline phosphatase reaction was followed at 405 nm.
2.5. Lipid analysis
Membrane lipids were extracted from 10U106 K562 cells as de-
scribed [18]. The amount of cholesterol in membranes was determined
after hydrolysis of the lipid extracts in methanol/5 M KOH (4:1, by
vol.) for 30 min at 60‡C under argon, followed by chromatographic
extraction on octadecyl-SPE columns (Baker). Cholesterol content
was determined as described [20]. Exposure of phosphatidylserine
on K562 cell membranes was determined by measuring £uorescence
of FITC-labelled annexin V [26]. Arachidonate metabolite leukotriene
B4 (LTB4) was extracted from K562 cells on octadecyl-SPE columns
(Baker) and was analyzed by reversed-phase high performance liquid
chromatography (RP-HPLC) on a C18 3U3 CR column (SGE), as
described [24]. RP-HPLC was performed on a Perkin Elmer 1022 LC
Plus liquid chromatograph at a £ow rate of 1.2 ml/min, using meth-
anol/water/tri£uoroacetic acid (70:30:0.07, by vol.) as mobile phase.
Chromatograms were recorded at 270 nm, assessing peak identity by
comparison with authentic standards. Quantitative determinations
were performed by integrating peak areas of each compound.
2.6. Data analysis
Data reported in this paper are the mean ( þ S.D.) of at least three
independent determinations, each performed in duplicate. Statistical
analysis was performed by the Student’s t-test and experimental data
were elaborated using the InStat program (GraphPad Software).
3. Results and discussion
Although the ability of tamoxifen (Tmx) to induce apopto-
sis in human breast cancer cells has been reported by our
group [6] and others [7,8], the biochemical events responsible
for the activity of the drug still await clari¢cation. Knowledge
of at least some of these events might be exploited to improve
the clinical e⁄cacy of the drug in the chemotherapy of cancer.
Treatment of human erythroleukemia K562 cells with 1 WM
Tmx induced an 8-fold increase in the number of apoptotic
cells after 48 h of exposure (Fig. 1), from 2.5% to 20%. K562
cells were more sensitive to Tmx than MCF-7G cells, where a
2-fold increase in PCD was observed under the same exper-
imental conditions [6]. In order to better characterize the bio-
chemical events leading to Tmx-induced PCD, apoptotic
K562 cells were enriched by gradient centrifugation on Lym-
pholyte-H medium. After three rounds, a fraction containing
80% apoptotic cells was separated, whereas a fourth round of
centrifugation did not further enhance the percentage of
apoptotic cells (data not shown). Therefore, K562 cells sub-
jected to three rounds of centrifugation were used to inves-
tigate the biochemical background of Tmx-induced PCD.
Tmx induced a remarkable increase in the activity and expres-
sion (at the protein level) of nitric oxide synthase in K562 cells
(Table 1), suggesting that the free radical nitric oxide might
play a role in the execution of PCD induced by the drug. This
concept was con¢rmed using the speci¢c inhibitor of nitric
oxide synthase, L-NAME [27], and the nitric oxide donor,
SNP. Fig. 1A shows the results obtained upon exposure of
K562 cells to concentrations of L-NAME (400 WM) and SNP
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Table 1
E¡ect of tamoxifen (Tmx) on the activity and expression of nitric oxide synthase and 5-lipoxygenase in K562 cellsz
Sample Nitric oxide synthase 5-Lipoxygenase
Activity (%) Protein level (%) Activity (%) Protein level (%)
K562 control 100a 100b 100c 100d
K562+Tmx 315 þ 30* 280 þ 30* 150 þ 15** 160 þ 15**
a100% = 25.0 þ 2.2 pmol citrulline/min/mg protein.
b100% = 0.18 þ 0.02 absorbance units at 405 nm.
c100% = 0.42 þ 0.04 nmol 5-HPETE/min/mg protein.
d100% = 0.25 þ 0.03 absorbance units at 405 nm.
*Denotes P6 0.01 compared to control. **Denotes P6 0.05 compared to control. Values are expressed as percentage of the untreated control,
Table 2
E¡ect of tamoxifen (Tmx) on leukotriene B4, phosphatidylserine exposure and membrane cholesterol content in K562 cells
Sample Leukotriene B4 (%) Phosphatidylserine exposure (%) Cholesterol (%)
K562 control 100a 100b 100c
K562+Tmx 202 þ 20* 275 þ 25** 171 þ 15*
a100% = 2.5 þ 0.2 pg/1036 cells.
b100% = 5 þ 0.5U104 annexin V-positive cells every 106 cells.
c100% = 3.2 þ 0.3 nmol/1036 cells.
*Denotes P6 0.05 compared to control. **Denotes P6 0.01 compared to control. Values are expressed as percentage of the untreated control,
arbitrarily set to 100.
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(2 mM) found to be optimal in pilot experiments (data not
shown). L-NAME e⁄ciently protected K562 cells against
Tmx-induced apoptosis, whereas SNP doubled the e¡ect of
the drug (Fig. 1A). Interestingly, nitric oxide was e¡ective in
the physiological micromolar range, since millimolar concen-
trations of SNP release micromolar concentrations of free
nitric oxide [15].
Nitric oxide is known to modulate the arachidonate cascade
catalyzed by lipoxygenase [28] and is a key molecule in the
execution of PCD in di¡erent experimental models [15]. Treat-
ment of K562 cells with Tmx also up-regulated 5-lipoxygenase
(EC 1.13.11.34) activity and expression, by 150% and 160%,
respectively, compared to controls (Table 1). 5-Lipoxygenase
was shown to be linked to Tmx-induced PCD by a cause-
e¡ect relationship using a speci¢c inhibitor or product of
the enzyme. Fig. 1B shows that 100 WM MK886, a 5-lipoxy-
genase-speci¢c inhibitor [29], protected K562 cells against
Tmx-induced apoptosis, whereas the 5-lipoxygenase product,
5-HPETE (used at 5 WM ¢nal concentration), signi¢cantly
enhanced the e¡ect of the drug (Fig. 1B). In addition, the
increase in 5-lipoxygenase activity and expression was paral-
leled by increased leukotriene B4 (LTB4), a speci¢c product of
5-lipoxygenase (Table 2). LTB4 plays a role in lipid-mediated
signal transduction [30] and is involved in PCD [19]. These
results extend previous observations on the involvement of the
5-lipoxygenase pathway in PCD induced by oxidative stress in
human cells [19], and suggest that reactive oxygen species
generated by 5-lipoxygenase (mainly lipid peroxides) might
take part in the apoptotic programme induced by Tmx.
Table 2 shows that exposure of K562 cells to Tmx altered
membrane lipids, increasing both phosphatidylserine exposure
(up to 275%) and cholesterol content (up to 170% of the
control). The observation that Tmx enhanced membrane cho-
lesterol content con¢rms previous ¢ndings on K562 cells
forced into apoptosis by transforming growth factor L1, alone
or in combination with cisplatin [18]. It further supports the
concept that membrane cholesterol is an important element in
the execution of PCD, as recently found in the same cell line
[20]. The increased cholesterol content in the lipid bilayer
leads to increased membrane rigidity [20], and this feature,
together with the exposure of speci¢c signals, such as phos-
phatidylserine, on the membrane surface (Table 2), might im-
prove recognition of apoptotic cells and removal by macro-
phages [31].
Altogether, the results reported herein show that tamoxifen,
a widely used chemotherapeutic agent, induces apoptosis in
human erythroleukemia K562 cells by activating nitric oxide
synthase. Furthermore, the enhancement of the activity and
expression of the membrane-related enzyme, 5-lipoxygenase,
plays a role in the execution of the death programme, which is
indeed characterized by altered membrane properties. These
¢ndings might be of clinical relevance and help to improve the
chemotherapeutic use of tamoxifen.
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